APO Research
Talk to an analyst

APO RESEARCH · REPORT

P53 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global P53 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025207 pages

Choose your research edition.

Industry ResearchP53 Antibody Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal P53 Antibody Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal P53 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal P53 Antibody Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal P53 Antibody Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global P53 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for P53 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for P53 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for P53 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the P53 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the P53 Antibody market include Thermo Fisher Scientific, Merck, Boster Biological Technology, United States Biological, Santa Cruz Biotechnology, Proteintech, NSJ Bioreagents, Miltenyi Biotec and Medimabs, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global P53 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of P53 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents P53 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global P53 Antibody market.

P53 Antibody Segment by Company

Thermo Fisher Scientific

Merck

Boster Biological Technology

United States Biological

Santa Cruz Biotechnology

Proteintech

NSJ Bioreagents

Miltenyi Biotec

Medimabs

Leica Biosystems

FineTest

EXBIO

Cell Signaling Technology

Bio-Rad

Beckman Coulter

Aviva Systems Biology

Atlas Antibodies

P53 Antibody Segment by Type

Polyclonal

Monoclonal

P53 Antibody Segment by Application

Immunohistochemistry

Immunocytochemistry

Immunoprecipitation

Enzyme Linked Immunosorbent Assay

Others

P53 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global P53 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the P53 Antibody key companies, revenue, market share, and recent developments.

3. To split the P53 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions P53 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify P53 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze P53 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global P53 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of P53 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of P53 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global P53 Antibody industry.

Chapter 3: Detailed analysis of P53 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of P53 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of P53 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. P53 Antibody Industry Trends Table 2. P53 Antibody Industry Drivers Table 3. P53 Antibody Industry Opportunities and Challenges Table 4. P53 Antibody Industry Restraints Table 5. Global P53 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global P53 Antibody Revenue Share by Company (2021-2026) Table 7. Global P53 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global P53 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global P53 Antibody Company, Product Type & Application Table 10. Global P53 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global P53 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global P53 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global P53 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global P53 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global P53 Antibody Sales Value Share by Type (2021-2026) Table 20. Global P53 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Table 22. Significant Companies of Immunocytochemistry Table 23. Significant Companies of Immunoprecipitation Table 24. Significant Companies of Enzyme Linked Immunosorbent Assay Table 25. Significant Companies of Others Table 26. Global P53 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global P53 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global P53 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global P53 Antibody Sales Value Share by Application (2021-2026) Table 30. Global P53 Antibody Sales Value Share by Application (2027-2032) Table 31. Global P53 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global P53 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global P53 Antibody Sales Value Share by Region (2021-2026) Table 34. Global P53 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global P53 Antibody Sales Value Share by Region (2027-2032) Table 36. Global P53 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global P53 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global P53 Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global P53 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global P53 Antibody Sales Value Market Share by Country (2027-2032) Table 41. Thermo Fisher Scientific Company Information Table 42. Thermo Fisher Scientific Business Overview Table 43. Thermo Fisher Scientific P53 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Thermo Fisher Scientific P53 Antibody Product Portfolio Table 45. Thermo Fisher Scientific Recent Development Table 46. Merck Company Information Table 47. Merck Business Overview Table 48. Merck P53 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Merck P53 Antibody Product Portfolio Table 50. Merck Recent Development Table 51. Boster Biological Technology Company Information Table 52. Boster Biological Technology Business Overview Table 53. Boster Biological Technology P53 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Boster Biological Technology P53 Antibody Product Portfolio Table 55. Boster Biological Technology Recent Development Table 56. United States Biological Company Information Table 57. United States Biological Business Overview Table 58. United States Biological P53 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. United States Biological P53 Antibody Product Portfolio Table 60. United States Biological Recent Development Table 61. Santa Cruz Biotechnology Company Information Table 62. Santa Cruz Biotechnology Business Overview Table 63. Santa Cruz Biotechnology P53 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Santa Cruz Biotechnology P53 Antibody Product Portfolio Table 65. Santa Cruz Biotechnology Recent Development Table 66. Proteintech Company Information Table 67. Proteintech Business Overview Table 68. Proteintech P53 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Proteintech P53 Antibody Product Portfolio Table 70. Proteintech Recent Development Table 71. NSJ Bioreagents Company Information Table 72. NSJ Bioreagents Business Overview Table 73. NSJ Bioreagents P53 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. NSJ Bioreagents P53 Antibody Product Portfolio Table 75. NSJ Bioreagents Recent Development Table 76. Miltenyi Biotec Company Information Table 77. Miltenyi Biotec Business Overview Table 78. Miltenyi Biotec P53 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Miltenyi Biotec P53 Antibody Product Portfolio Table 80. Miltenyi Biotec Recent Development Table 81. Medimabs Company Information Table 82. Medimabs Business Overview Table 83. Medimabs P53 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Medimabs P53 Antibody Product Portfolio Table 85. Medimabs Recent Development Table 86. Leica Biosystems Company Information Table 87. Leica Biosystems Business Overview Table 88. Leica Biosystems P53 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Leica Biosystems P53 Antibody Product Portfolio Table 90. Leica Biosystems Recent Development Table 91. FineTest Company Information Table 92. FineTest Business Overview Table 93. FineTest P53 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. FineTest P53 Antibody Product Portfolio Table 95. FineTest Recent Development Table 96. EXBIO Company Information Table 97. EXBIO Business Overview Table 98. EXBIO P53 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. EXBIO P53 Antibody Product Portfolio Table 100. EXBIO Recent Development Table 101. Cell Signaling Technology Company Information Table 102. Cell Signaling Technology Business Overview Table 103. Cell Signaling Technology P53 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Cell Signaling Technology P53 Antibody Product Portfolio Table 105. Cell Signaling Technology Recent Development Table 106. Bio-Rad Company Information Table 107. Bio-Rad Business Overview Table 108. Bio-Rad P53 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Bio-Rad P53 Antibody Product Portfolio Table 110. Bio-Rad Recent Development Table 111. Beckman Coulter Company Information Table 112. Beckman Coulter Business Overview Table 113. Beckman Coulter P53 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Beckman Coulter P53 Antibody Product Portfolio Table 115. Beckman Coulter Recent Development Table 116. Aviva Systems Biology Company Information Table 117. Aviva Systems Biology Business Overview Table 118. Aviva Systems Biology P53 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Aviva Systems Biology P53 Antibody Product Portfolio Table 120. Aviva Systems Biology Recent Development Table 121. Atlas Antibodies Company Information Table 122. Atlas Antibodies Business Overview Table 123. Atlas Antibodies P53 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Atlas Antibodies P53 Antibody Product Portfolio Table 125. Atlas Antibodies Recent Development Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. P53 Antibody Product Image Figure 2. Global P53 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global P53 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global P53 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global P53 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global P53 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global P53 Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Image Figure 13. Immunocytochemistry Image Figure 14. Immunoprecipitation Image Figure 15. Enzyme Linked Immunosorbent Assay Image Figure 16. Others Image Figure 17. Global P53 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global P53 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global P53 Antibody Sales Value Share by Application (2021-2032) Figure 20. Global P53 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global P53 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America P53 Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America P53 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe P53 Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe P53 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific P53 Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific P53 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America P53 Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America P53 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa P53 Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa P53 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt P53 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt P53 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt P53 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry
  • Immunocytochemistry
  • Immunoprecipitation
  • Enzyme Linked Immunosorbent Assay
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Merck
  • Boster Biological Technology
  • United States Biological
  • Santa Cruz Biotechnology
  • Proteintech
  • NSJ Bioreagents
  • Miltenyi Biotec
  • Medimabs
  • Leica Biosystems
  • FineTest
  • EXBIO
  • Cell Signaling Technology
  • Bio-Rad
  • Beckman Coulter
  • Aviva Systems Biology
  • Atlas Antibodies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global P53 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global P53 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 P53 Antibody Market Dynamics
  1. 2.1 P53 Antibody Industry Trends
  2. 2.2 P53 Antibody Industry Drivers
  3. 2.3 P53 Antibody Industry Opportunities and Challenges
  4. 2.4 P53 Antibody Industry Restraints
3 P53 Antibody Market by Company
  1. 3.1 Global P53 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global P53 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global P53 Antibody Company Ranking (2024-2026)
  4. 3.4 Global P53 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global P53 Antibody Company Product Type and Application
  6. 3.6 Global P53 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global P53 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 P53 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 P53 Antibody Market by Type
  1. 4.1 P53 Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global P53 Antibody Sales Value by Type
  5. 4.2.1 Global P53 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global P53 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global P53 Antibody Sales Value Share by Type (2021-2032)
5 P53 Antibody Market by Application
  1. 5.1 P53 Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry
  3. 5.1.2 Immunocytochemistry
  4. 5.1.3 Immunoprecipitation
  5. 5.1.4 Enzyme Linked Immunosorbent Assay
  6. 5.1.5 Others
  7. 5.2 Global P53 Antibody Sales Value by Application
  8. 5.2.1 Global P53 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global P53 Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global P53 Antibody Sales Value Share by Application (2021-2032)
6 P53 Antibody Regional Value Analysis
  1. 6.1 Global P53 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global P53 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global P53 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global P53 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America P53 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America P53 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe P53 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe P53 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific P53 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific P53 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America P53 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America P53 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa P53 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa P53 Antibody Sales Value Share by Country, 2025 VS 2032
7 P53 Antibody Country-level Value Analysis
  1. 7.1 Global P53 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global P53 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global P53 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global P53 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA P53 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA P53 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA P53 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada P53 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada P53 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada P53 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico P53 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico P53 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico P53 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany P53 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany P53 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany P53 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France P53 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France P53 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France P53 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. P53 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. P53 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. P53 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy P53 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy P53 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy P53 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain P53 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain P53 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain P53 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia P53 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia P53 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia P53 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands P53 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands P53 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands P53 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries P53 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries P53 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries P53 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China P53 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China P53 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China P53 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan P53 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan P53 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan P53 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea P53 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea P53 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea P53 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India P53 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India P53 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India P53 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia P53 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia P53 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia P53 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia P53 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia P53 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia P53 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil P53 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil P53 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil P53 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina P53 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina P53 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina P53 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile P53 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile P53 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile P53 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia P53 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia P53 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia P53 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru P53 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru P53 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru P53 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia P53 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia P53 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia P53 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel P53 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel P53 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel P53 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE P53 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE P53 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE P53 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey P53 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey P53 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey P53 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran P53 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran P53 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran P53 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt P53 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt P53 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt P53 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific P53 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific P53 Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck P53 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck P53 Antibody Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Boster Biological Technology
  14. 8.3.1 Boster Biological Technology Company Information
  15. 8.3.2 Boster Biological Technology Business Overview
  16. 8.3.3 Boster Biological Technology P53 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boster Biological Technology P53 Antibody Product Portfolio
  18. 8.3.5 Boster Biological Technology Recent Developments
  19. 8.4 United States Biological
  20. 8.4.1 United States Biological Company Information
  21. 8.4.2 United States Biological Business Overview
  22. 8.4.3 United States Biological P53 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 United States Biological P53 Antibody Product Portfolio
  24. 8.4.5 United States Biological Recent Developments
  25. 8.5 Santa Cruz Biotechnology
  26. 8.5.1 Santa Cruz Biotechnology Company Information
  27. 8.5.2 Santa Cruz Biotechnology Business Overview
  28. 8.5.3 Santa Cruz Biotechnology P53 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Santa Cruz Biotechnology P53 Antibody Product Portfolio
  30. 8.5.5 Santa Cruz Biotechnology Recent Developments
  31. 8.6 Proteintech
  32. 8.6.1 Proteintech Company Information
  33. 8.6.2 Proteintech Business Overview
  34. 8.6.3 Proteintech P53 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Proteintech P53 Antibody Product Portfolio
  36. 8.6.5 Proteintech Recent Developments
  37. 8.7 NSJ Bioreagents
  38. 8.7.1 NSJ Bioreagents Company Information
  39. 8.7.2 NSJ Bioreagents Business Overview
  40. 8.7.3 NSJ Bioreagents P53 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 NSJ Bioreagents P53 Antibody Product Portfolio
  42. 8.7.5 NSJ Bioreagents Recent Developments
  43. 8.8 Miltenyi Biotec
  44. 8.8.1 Miltenyi Biotec Company Information
  45. 8.8.2 Miltenyi Biotec Business Overview
  46. 8.8.3 Miltenyi Biotec P53 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Miltenyi Biotec P53 Antibody Product Portfolio
  48. 8.8.5 Miltenyi Biotec Recent Developments
  49. 8.9 Medimabs
  50. 8.9.1 Medimabs Company Information
  51. 8.9.2 Medimabs Business Overview
  52. 8.9.3 Medimabs P53 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medimabs P53 Antibody Product Portfolio
  54. 8.9.5 Medimabs Recent Developments
  55. 8.10 Leica Biosystems
  56. 8.10.1 Leica Biosystems Company Information
  57. 8.10.2 Leica Biosystems Business Overview
  58. 8.10.3 Leica Biosystems P53 Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Leica Biosystems P53 Antibody Product Portfolio
  60. 8.10.5 Leica Biosystems Recent Developments
  61. 8.11 FineTest
  62. 8.11.1 FineTest Company Information
  63. 8.11.2 FineTest Business Overview
  64. 8.11.3 FineTest P53 Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 FineTest P53 Antibody Product Portfolio
  66. 8.11.5 FineTest Recent Developments
  67. 8.12 EXBIO
  68. 8.12.1 EXBIO Company Information
  69. 8.12.2 EXBIO Business Overview
  70. 8.12.3 EXBIO P53 Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 EXBIO P53 Antibody Product Portfolio
  72. 8.12.5 EXBIO Recent Developments
  73. 8.13 Cell Signaling Technology
  74. 8.13.1 Cell Signaling Technology Company Information
  75. 8.13.2 Cell Signaling Technology Business Overview
  76. 8.13.3 Cell Signaling Technology P53 Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cell Signaling Technology P53 Antibody Product Portfolio
  78. 8.13.5 Cell Signaling Technology Recent Developments
  79. 8.14 Bio-Rad
  80. 8.14.1 Bio-Rad Company Information
  81. 8.14.2 Bio-Rad Business Overview
  82. 8.14.3 Bio-Rad P53 Antibody Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bio-Rad P53 Antibody Product Portfolio
  84. 8.14.5 Bio-Rad Recent Developments
  85. 8.15 Beckman Coulter
  86. 8.15.1 Beckman Coulter Company Information
  87. 8.15.2 Beckman Coulter Business Overview
  88. 8.15.3 Beckman Coulter P53 Antibody Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Beckman Coulter P53 Antibody Product Portfolio
  90. 8.15.5 Beckman Coulter Recent Developments
  91. 8.16 Aviva Systems Biology
  92. 8.16.1 Aviva Systems Biology Company Information
  93. 8.16.2 Aviva Systems Biology Business Overview
  94. 8.16.3 Aviva Systems Biology P53 Antibody Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Aviva Systems Biology P53 Antibody Product Portfolio
  96. 8.16.5 Aviva Systems Biology Recent Developments
  97. 8.17 Atlas Antibodies
  98. 8.17.1 Atlas Antibodies Company Information
  99. 8.17.2 Atlas Antibodies Business Overview
  100. 8.17.3 Atlas Antibodies P53 Antibody Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Atlas Antibodies P53 Antibody Product Portfolio
  102. 8.17.5 Atlas Antibodies Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst